Bangladesh's Beximco Pharmaceuticals is investing in Serum Institute of India (SII) for Coronavirus vaccine deal

Bangladesh's Beximco Pharmaceuticals is investing in Serum Institute of India (SII) for Coronavirus vaccine deal

Sponsor
Bangladesh and India companies have  signed Coronavirus ( Covid-19) vaccine deal

Bangladesh and India companies have  signed Coronavirus (Covid-19) vaccine deal. In this regard, the Bangladesh's Beximco Pharmaceuticals is investing in the Serum Institute of India (SII) to ensure Dhaka gets priority access to COVID-19 vaccines being developed by the Indian drug manufacturer, said the company.

The deal announced by the Bangladeshi generic drugmaker comes after Dhaka said this month it was ready to hold trials of candidate vaccines being developed by India as both countries seek to curb the spread of the virus.

SII has partnered with AstraZeneca, the Gates Foundation and the Gavi vaccine alliance to produce more than a billion doses of a COVID-19 vaccine for global supply.

"This landmark agreement reflects the deep-rooted desire for collaboration between the two countries and as representatives of the two nations, between us we can go a long way towards helping to mitigate the health crisis caused by the COVID-19 pandemic," the heads of both companies said in the statement.
                                                                
Sponsor